Sequencing Therapies in Steroid-Refractory Chronic GVHD

Video

Dr Yi-Bin Chen discusses the indications of ibrutinib, ruxolitinib, and belumosudil in steroid-refractory chronic graft-vs-host disease and shares his approach to selecting the optimal therapy for patients.

Matt Fowler: Can you briefly touch on the indications that each of these are approved on and get into maybe the age requirements or previous lines of therapy?

Yi-Bin Chen, MD: There are subtle differences in the approval labels for each of these 3 agents for steroid-refractory chronic graft-vs-host disease. Ibrutinib [Imbruvica] is only approved for adults who have failed 1 or more lines of therapy for chronic graft-vs-host disease [GVHD]. Belumosudil [Rezurock] is approved for patients 12 years and older, but it was only studied in patients who had failed at least 2 lines of therapy. It’s approved really for third-line therapy in chronic graft-vs-host disease. Ruxolitinib [Jakafi] is approved for patients 12 years and older as well, having failed at least 1 line of therapy. That’s how they’re all approved right now. We haven’t seen any data for them to be used in combination, though many of us are doing that. We also don’t know how long to use these agents for, and also how to stop them if they’re not working. All of these things bear future study.

Matt Fowler: With these 3 options, which regimens do you use the most in patients with steroid-refractory disease? Really, what factors go into influencing the treatment choice for patients?

Yi-Bin Chen, MD: I’m often asked, with these new agents, how do I sequence them in our patients? After steroids, if their patients are steroid-refractory, steroid-dependent, or need another agent for different reasons, our standard right now is ruxolitinib. It’s been that way even before approval because of how well tolerated ruxolitinib was and how well it was working. I would guess at least three-quarters of the patients I’ve started on ruxolitinib for chronic GVHD have had some kind of benefit. I tend to use that first. If that is not efficacious, or it works yet we need something else, then I generally have a discussion with the patient around belumosudil, photophoresis, or any clinical trials that we may have open. There’s a lot of discussion around those options and what makes the most sense for patients depending on their clinical manifestations, how enthusiastic they may be for certain clinical trials we have open, how OK they are to tolerate the logistics of doing photophoresis as a therapy itself. All those things go into play to figure out what we should use for third-line therapy.

Transcript Edited for Clarity

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content
Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib

Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib

ONCOLOGY Staff
November 16th 2024
Article

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202

American Society for Transplantation and Cellular Therapy
October 30th 2024
Article

Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Lower-Risk MDS Population Has Enduring RBC-TI Following Imetelstat Therapy

Ashling Wahner
September 8th 2024
Article

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.

Subcutaneous Daratumumab Combo Improves MRD-Negative Status in NDMM

Chris Ryan
September 7th 2024
Article

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.